We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TURSG:BISTTurkiye Sigorta A.S. Analysis

Data as of 2026-05-20 - not real-time

TRY 13.34

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Türkiye Sigorta A.S. displays a compelling fundamentals backdrop, with revenue growth of 29% YoY, a robust profit margin of 22.9% and an extraordinary ROE of 49% that underscores its profitability. The balance sheet is exceptionally strong, featuring over 103 billion TRY in cash against a modest 131 million TRY debt, resulting in a low debt‑to‑equity of 0.24. Valuation metrics reinforce the upside narrative: a trailing P/E of 6.8 versus the industry average of 16.5, a forward P/E of 3.8, and a DCF‑derived fair value of ~20.7 TRY, implying roughly 37% upside from the current 13.34 TRY price. Dividend sustainability looks solid, with a 2.19% yield and a modest 10% payout ratio supported by ample liquidity.
On the technical side, the stock sits just above its near‑term support of 13.25 TRY but below the 20‑day SMA of 14.15 TRY, while the MACD histogram remains negative, hinting at short‑term bearish pressure. Nevertheless, volume is increasing and the broader trend is flagged bullish, with a low beta of 0.18 indicating limited market‑wide volatility. The market sentiment is in an "Extreme Greed" phase, and despite a high 30‑day volatility of 42%, the combination of strong fundamentals and attractive valuation positions the stock as a potential upside play.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price is hovering just above the identified support level of 13.25 TRY
  • MACD histogram is negative, suggesting short‑term bearish momentum
  • Increasing trading volume indicates growing market interest

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Revenue growth of 29% combined with a profit margin above 22%
  • Trailing P/E of 6.8 far below the industry average of 16.5
  • DCF fair‑value estimate provides ~37% upside potential

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Exceptional ROE of 49% and strong cash generation
  • Very low debt‑to‑equity ratio (0.24) ensuring financial stability
  • Sustainable dividend yield of 2.2% with a low payout ratio

Key Metrics & Analysis

Financial Health

Revenue Growth29.20%
Profit Margin22.90%
P/E Ratio6.8
ROE49.39%
ROA11.79%
Debt/Equity0.24
P/B Ratio2.7
Op. Cash FlowTRY4.2B
Free Cash FlowTRY-14267836416
Industry P/E16.5

Technical Analysis

TrendBullish
RSI42.6
SupportTRY 13.25
ResistanceTRY 14.99
MA 20TRY 14.15
MA 50TRY 13.47
MA 200TRY 11.78
MACDBearish
VolumeIncreasing
Fear & Greed Index89.38

Valuation

Fair ValueTRY 20.68
Target PriceTRY 18.31
Upside/Downside37.28%
GradeUndervalued
TypeBlend
Dividend Yield2.19%

Risk Assessment

Beta0.18
Volatility42.44%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskHigh
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.